ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

Company Overview - ScPharmaceuticals, Inc. (SCPH) is expected to report a quarterly loss of $0.40 per share, reflecting a year-over-year decline of 14.3$12.04 million, which represents a significant increase of 97.4% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for ScPharmaceuticals is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.50%, suggesting a bullish outlook from analysts [10] Historical Performance - In the last reported quarter, ScPharmaceuticals was expected to post a loss of $0.30 per share but actually reported a loss of$0.37, resulting in a surprise of -23.33% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - Another company in the same industry, BioXcel Therapeutics, Inc. (BTAI), is expected to report a loss of $4.36 per share, indicating a year-over-year change of +64.1$0.15 million [17] - BioXcel's consensus EPS estimate has remained unchanged, but a lower Most Accurate Estimate has led to a negative Earnings ESP of -15.50%, complicating predictions for an earnings beat [18]